Obesity affects a large percentage of patients in the United States and is associated with increased mortality and higher healthcare costs. Newer guidelines recommend a minimum of 10% weight loss goal for patients with obesity, and medical management options fall short. Tirzepatide, the first available dual-incretin analog, is a novel treatment for type 2 diabetes that also can induce weight loss. This article discusses tirzepatide as a treatment for obesity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.JAA.0000979484.51712.33 | DOI Listing |
Publication Analysis
Top Keywords
weight loss
8
tirzepatide promising
4
promising treatment
4
treatment obesity?
4
obesity? obesity
4
obesity large
4
large percentage
4
percentage patients
4
patients united
4
united states
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!